StreetAlpha.app
Home › Stocks › ANNX

Annexon, Inc. (ANNX)

Healthcare
$3.47
▼ −2.80%
LAST CLOSE · NOV 17

Annexon is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases of the body, brain and eye. It last closed at $3.47 on Nov 17, down 2.80% on the day. The average 12-month price target from 2 analysts is $20.00 (+476.4% from the last close), with a high of $25.00 and a low of $15.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in ANNX, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints totaling $308K, the largest $170K.

AI Auto Pilots
Is ANNX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$199.0M
EPS (diluted)
−$1.01
Free cash flow
−$189.5M
Balance sheet
Cash & equivalents
$102.4M
At Sep 30
Debt
$49.3M
At Sep 30
Shareholder equity
$142.8M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$130.3M−$130.3MFY2021FY2022: −$141.9M−$141.9MFY2022FY2023: −$134.2M−$134.2MFY2023FY2024: −$138.2M−$138.2MFY2024FY2025: −$206.7M−$206.7MFY2025

From ANNX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated ANNX in the past 90 days, not enough for a consensus
Average 12-month target
$20.00
▲ 476.4% upside

Based on 2 analysts who set a price target on ANNX in the past 90 days. The average target is $20.00, with a high of $25.00 and a low of $15.00, compared with the last close of $3.47.

Low $15.00Avg $20.00High $25.00
Blue marker: last close $3.47
Highest target$25.00
Average target$20.00
Lowest target$15.00
Latest rating changes
HC Wainwright & Co.Maintained
Oct 19Buy$25
JP MorganTarget raised
Sep 30Buy$14 → $15
JP MorganMaintained
Sep 1Buy$14
CitizensInitiated
Jul 21Sell$3
NeedhamMaintained
Jul 15Buy$25
DateFirmActionRatingPrice target
Oct 19HC Wainwright & Co.MaintainedBuy$25
Sep 30JP MorganTarget raisedBuy$14 → $15
Sep 1JP MorganMaintainedBuy$14
Jul 21CitizensInitiatedSell$3
Jul 15NeedhamMaintainedBuy$25
Loading…

Technical Analysis

ANNX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 14% below its 20 day and 15% below its 50 day average. It is 46% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $3.36, and the nearest resistance the Pivot at $3.48.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.6%/day
Key levels
$7.1852 week high+106.9%
$5.07200 day average+46.1%
$4.67100 day average+34.6%
$4.07Swing high (Oct 21)+17.3%
$3.9850 day average+14.7%
$3.9620 day average+14.1%
$3.58Pivot R1+3.2%
$3.48Pivot+0.3%
$3.47Last close
$3.36Pivot S1−3.2%
$3.36Swing low (Oct 16)−3.2%
$2.6752 week low−23.1%
Indicators
RSI (14)35.73Weak, oversold below 30Neutral
MACD-0.06Below its signal lineBearish
Stochastic13.2Near the bottom of its rangeOversold
ADX (14)15.5No clear trend
Williams %R-90.9Oversold below −80, overbought above −20Oversold
CCI (20)-191.1Oversold below −100, overbought above 100Oversold
Rate of change−17.2%Change over 10 sessionsBearish
ATR (14)$0.26Typical daily range, 7.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANNX

What happened before

See how ANNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ANNX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ANNX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Oct 21 – Oct 21
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$308K
Largest print
$170K
Loading…

ANNX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●112 buying vs 98 selling
  • ▲Shares held by funds +10.0%
  • ▼Funds holding -12
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding205217−5.5%
In funds' top 10440.0%
Held by funds–––
New / increased31 / 8129 / 79+3.7%
Reduced / sold out58 / 4079 / 28−8.4%
Put/call ratio0.680.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANNX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANNX is in one of them and how their past ANNX trades turned out.

ANNX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANNX in an article yet. Here's the latest on the wider market.

About Annexon

Annexon is a biopharmaceutical company based in Brisbane, California. It develops drug candidates that target C1q, an early step in the classical complement pathway, a part of the immune system that can drive inflammation and tissue damage. Its main programs address neuroinflammatory diseases of the body, brain and eye, including Guillain-Barré Syndrome, geographic atrophy and autoimmune conditions. The company is developing these treatments for patients and does not yet have an approved product.

Headquarters
Brisbane, CA